182 related articles for article (PubMed ID: 22976763)
1. Non-physiological amino acid (NPAA) therapy targeting brain phenylalanine reduction: pilot studies in PAHENU2 mice.
Vogel KR; Arning E; Wasek BL; Bottiglieri T; Gibson KM
J Inherit Metab Dis; 2013 May; 36(3):513-23. PubMed ID: 22976763
[TBL] [Abstract][Full Text] [Related]
2. Characterization of 2-(methylamino)alkanoic acid capacity to restrict blood-brain phenylalanine transport in Pah enu2 mice: preliminary findings.
Vogel KR; Arning E; Wasek BL; Bottiglieri T; Gibson KM
Mol Genet Metab; 2013; 110 Suppl(0):S71-8. PubMed ID: 23999161
[TBL] [Abstract][Full Text] [Related]
3. Physiological Competition of Brain Phenylalanine Accretion: Initial Pharmacokinetic Analyses of Aminoisobutyric and Methylaminoisobutyric Acids in
Vogel KR; Ainslie GR; Phillips B; Arning E; Bottiglieri T; Shen DD; Gibson KM
Mol Genet Metab Rep; 2015 Jun; 3():80-87. PubMed ID: 26120559
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic brain modulation with targeted large neutral amino acid supplements in the Pah-enu2 phenylketonuria mouse model.
van Vliet D; Bruinenberg VM; Mazzola PN; van Faassen MH; de Blaauw P; Pascucci T; Puglisi-Allegra S; Kema IP; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
Am J Clin Nutr; 2016 Nov; 104(5):1292-1300. PubMed ID: 27655443
[TBL] [Abstract][Full Text] [Related]
5. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.
Pietz J; Kreis R; Rupp A; Mayatepek E; Rating D; Boesch C; Bremer HJ
J Clin Invest; 1999 Apr; 103(8):1169-78. PubMed ID: 10207169
[TBL] [Abstract][Full Text] [Related]
6. Future role of large neutral amino acids in transport of phenylalanine into the brain.
Matalon R; Surendran S; Matalon KM; Tyring S; Quast M; Jinga W; Ezell E; Szucs S
Pediatrics; 2003 Dec; 112(6 Pt 2):1570-4. PubMed ID: 14654667
[TBL] [Abstract][Full Text] [Related]
7. The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model.
Ahring KK; Dagnæs-Hansen F; Brüel A; Christensen M; Jensen E; Jensen TG; Johannsen M; Johansen KS; Lund AM; Madsen JG; Brøndum-Nielsen K; Pedersen M; Sørensen LK; Kjolby M; Møller LB
PLoS One; 2022; 17(1):e0261150. PubMed ID: 35015767
[TBL] [Abstract][Full Text] [Related]
8. Large Neutral Amino Acid Supplementation Exerts Its Effect through Three Synergistic Mechanisms: Proof of Principle in Phenylketonuria Mice.
van Vliet D; Bruinenberg VM; Mazzola PN; van Faassen MH; de Blaauw P; Kema IP; Heiner-Fokkema MR; van Anholt RD; van der Zee EA; van Spronsen FJ
PLoS One; 2015; 10(12):e0143833. PubMed ID: 26624009
[TBL] [Abstract][Full Text] [Related]
9. Large neutral amino acid supplementation as an alternative to the phenylalanine-restricted diet in adults with phenylketonuria: evidence from adult Pah-enu2 mice.
van Vliet D; van der Goot E; Bruinenberg VM; van Faassen M; de Blaauw P; Kema IP; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
J Nutr Biochem; 2018 Mar; 53():20-27. PubMed ID: 29175141
[TBL] [Abstract][Full Text] [Related]
10. Functional activity of a large neutral amino acid transporter (LAT) in rabbit retina: a study involving the in vivo retinal uptake and vitreal pharmacokinetics of L-phenyl alanine.
Atluri H; Talluri RS; Mitra AK
Int J Pharm; 2008 Jan; 347(1-2):23-30. PubMed ID: 17686592
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.
Sawin EA; Murali SG; Ney DM
Mol Genet Metab; 2014 Apr; 111(4):452-61. PubMed ID: 24560888
[TBL] [Abstract][Full Text] [Related]
12. Large neutral amino acids auto exchange when infused by microdialysis into the rat brain: implication for maple syrup urine disease and phenylketonuria.
Zielke HR; Zielke CL; Baab PJ; Collins RM
Neurochem Int; 2002 Apr; 40(4):347-54. PubMed ID: 11792465
[TBL] [Abstract][Full Text] [Related]
13. Correlations of blood and brain biochemistry in phenylketonuria: Results from the Pah-enu2 PKU mouse.
Dijkstra AM; van Vliet N; van Vliet D; Romani C; Huijbregts SCJ; van der Goot E; Hovens IB; van der Zee EA; Kema IP; Heiner-Fokkema MR; van Spronsen FJ
Mol Genet Metab; 2021 Nov; 134(3):250-256. PubMed ID: 34656426
[TBL] [Abstract][Full Text] [Related]
14. Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria.
Ney DM; Hull AK; van Calcar SC; Liu X; Etzel MR
J Nutr; 2008 Feb; 138(2):316-22. PubMed ID: 18203898
[TBL] [Abstract][Full Text] [Related]
15. The Benefit of Large Neutral Amino Acid Supplementation to a Liberalized Phenylalanine-Restricted Diet in Adult Phenylketonuria Patients: Evidence from Adult
van Vliet D; van der Goot E; van Ginkel WG; van Faassen MHJR; de Blaauw P; Kema IP; Martinez A; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
Nutrients; 2019 Sep; 11(9):. PubMed ID: 31546852
[TBL] [Abstract][Full Text] [Related]
16. The increasing importance of LNAA supplementation in phenylketonuria at higher plasma phenylalanine concentrations.
van Vliet D; van der Goot E; van Ginkel WG; van Faassen HJR; de Blaauw P; Kema IP; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
Mol Genet Metab; 2022 Jan; 135(1):27-34. PubMed ID: 34974973
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting neutral amino acid transport for the treatment of phenylketonuria.
Belanger AM; Przybylska M; Gefteas E; Furgerson M; Geller S; Kloss A; Cheng SH; Zhu Y; Yew NS
JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046012
[TBL] [Abstract][Full Text] [Related]
18. Of mice and men: Plasma phenylalanine reduction in PKU corrects neurotransmitter pathways in the brain.
Berguig GY; Martin NT; Creer AY; Xie L; Zhang L; Murphy R; Pacheco G; Bullens S; Olbertz J; Weng HH
Mol Genet Metab; 2019 Dec; 128(4):422-430. PubMed ID: 31648944
[TBL] [Abstract][Full Text] [Related]
19. Effects of dietary mixtures of amino acids on fetal growth and maternal and fetal amino acid pools in experimental maternal phenylketonuria.
Austic RE; Su CL; Strupp BJ; Levitsky DA
Am J Clin Nutr; 1999 Apr; 69(4):687-96. PubMed ID: 10197570
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of L-tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU).
Harding CO; Winn SR; Gibson KM; Arning E; Bottiglieri T; Grompe M
J Inherit Metab Dis; 2014 Sep; 37(5):735-43. PubMed ID: 24487571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
